【Oncolys BioPharma】Approval of Medical Insurance Handling｜June 2026

Overview of Business Performance

This document does not provide financial results for Oncolys BioPharma but is an announcement regarding the handling of the Telomere-Long regenerative medicine product in medical insurance. The product received manufacturing and marketing approval on June 8, 2026, and was approved for handling as a pharmaceutical by the Central Social Insurance Medical Council. It is planned to be listed in the drug price standard after deliberations, with sales scheduled to commence from the 2026 fiscal year ending December. There is no impact on our financial results due to this matter.

Future Outlook and Impact on Shareholders

With this approval, the handling of Telomere-Long in medical insurance is confirmed, and preparations for sales are underway. Revenue from sales is expected to start from the 2026 fiscal year ending December, which could influence future business development and earnings forecasts. While there is no direct impact on our financial results, attention should be paid to upcoming sales developments and revenue realization.